Table 2.

Incidence and survival in reported cardiogenic shock 2007–2017

	2007–2010		2011–2013		2014–2017		Total 2007–2017
	N	Survival	N	Survival	N	Survival	N	Survival
Whole cohort	113,053	39.5%	103,437	40.2%	167,493	40.6%	383,983	40.2%
Medical therapy	94,856	37.6%	89,585	39.2%	149,018	40.8%	333,459	39.5%
Any MCS	18,197	49.3%	13,852	46.9%	18,475	38.7%	50,524	44.8%
pVAD	196	33.2%	348	29.6%	3,401	37.0%	3,945	36.1%
IABP	17,693	49.9%	11,969	49.7%	7,143	48.3%	36,805	49.5%
VA-ECMO	308	25.6%	1,535	29.3%	7,931	30.9%	9,774	30.5%

The case numbers of cardiogenic shock incidence from 2007 to 2010, 2011 to 2013 and 2014 to 2017 as well as the total case numbers from 2007 to 2017 are shown. A constant rise of case numbers of cardiogenic shock is depicted. Additionally, the survival of the different cohorts is displayed in percentage grouped in medical or MCS therapy with subgroups of pVAD, IABP and VA-ECMO